Clinical Trial Update: Dacomitinib in Lung Cancer With Uncommon EGFR Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating dacomitinib in metastatic non-small cell lung cancer with uncommon EGFR mutations is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Non-small Cell Lung Cancer Metastatic, EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING